AzTrials
AzTrials

Severe ObesityCOBILOMNCT03538210

Obesity Cohort Bichat Louis Mourier

An observational study of Severe Obesity and Bariatric Surgery, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Obesity prevalence rapidly increased in the past decades in French population with multiple health consequences responsible for excess mortality. In the same period of time, the number of bariatric procedures have developed exponentially. Read more about this study

Who is it for?
Ages 18 to 65 years
How many people
360 participants
Where
1 siteFrance
Study dates
16 Feb 2018to 3 Mar 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: severe obese subjects operated for bariatric surgery or reoperated for complication

Who may be able to join

  • severe obese subject with BMI above35 kg/m2, age above 18 ans who accept to participate
  • candidate for bariatric surgery according to HAS criteria
  • who will undergo either sleeve gastrectomy or gastric bypass
  • or who undergoesa revisional surgery for a complication of bariatric surgery
  • or who undergoes arevisional sugery fir insufficient weight loss
  • covered by an health insurance

Who cannot join

  • psychiatric disease or undertanding disorder
  • alchool abuse or other addiction
  • organ failure (including liver, heart or kidney)
  • chronic life-threatening illness
  • inflamatory disease or immunosuppressive treatment

Trial locations and contacts

1 site in 1 country.

France1 site
  • Hôpital Lousi Mourier (HUPNVS)

    Colombes, Île-de-France Region, 92700

Other trials in France

About this study

Official title: Cohorte Obésité Bichat LOuis Mourier

Obesity prevalence rapidly increased in the past decades in French population with multiple health consequences responsible for excess mortality. In the same period of time, the number of bariatric procedures have developed exponentially. Despite its great efficacy on weight loss but also on resolution of comorbidities, bariatric surgery is not without risks. Our hypothesis is that a better understanding of the physio-pathological consequences of obesity and bariatric surgery, notably on the gastrointestinal tract, may allow to improve the treatment of obesity and to find alternatives to bariatric surgery.

The main objective of this cohort study is to systematize the collection and the conservation of biological samples (blood, stomach, liver, intestine, adipose tissue) obtained during bariatric surgery, in obese subjects undergoing surgery (including sleeve gastrectomy, Roux-en-Y gastric bypass, or revisional intervention for complication or weight regain) in the University Hospital group of Paris Nord Val de Seine (HYPNVS).

The main projects that will build on this cohort will cover the physiopathology of obesity and its consequences, notably in the field of gastrointestinal tract including: modification of gastro-intestinal plasticity in severe obesity and after bariatric surgery and alterations of absorption of nutriments (lipids, proteins, carbohydrates) induced by obesity and bariatric surgery. The inclusion in this project of obese subjects before surgery, or lean or obese subjects after surgery will allow to distinguish the impact of weight loss and surgery on gastrointestinal remodeling. This cohort will also allow to characterize stomach and intestinal proteome in severe obesity and to precise the influence of tissue inflammation on metabolic disorders associated with obesity.

Read the detailed description

The prevalence of obesity rapidly increased in the past decades in the French population with multiple health consequences (including hypertension, diabetes, sleep apnea syndrome, cardiovascular events, cancers…) responsible for excess mortality. In the same period of time, the number of bariatric procedures has developed exponentially. Indeed, there is presently little or no therapeutic alternatives in severe obesity, the pharmacotherapy of obesity having a poor efficacy. Despite its great efficacy on weight loss and resolution of comorbidities, bariatric surgery is not without risks. Indeed, it can be accompanied by side effects, including gastrointestinal disorders (transit disturbances, gastro-esophageal reflux, or dumping syndrome), surgical complications (gastric fistulas and bowel obstruction) and multiples nutritional deficiencies deleterious for health (anemia, neurological complication, bone loss, and protein malnutrition).

The mechanisms of development of obesity are still imperfectly known and, moreover, the observations made in murine models are not always transposable to humans. This is why it is necessary to establish human cohorts to specify better the pathophysiological mechanisms underlying the development of obesity and its complications and to identify new markers of response to medical and surgical treatments of obesity, in order to propose targeted therapies. In particular, the digestive tract, at the interface between the intake of nutrients and their metabolism, has a central role both in the development of obesity and in the effects of bariatric surgery.

Since 2000, bariatric surgery has been developed in University Hospital group of Paris Nord Val de Seine (HYPNVS) with a significant activity of about 600 procedures per year (mainly gastric bypass and sleeve gastrectomy). The well-systematized multidisciplinary clinical management makes it possible to phenotype the patients precisely. The collaboration between the obesity center and the INSERM 1149 research team promotes the implementation of transversal projects ranging from clinical research to basic research to deepen the physio-pathological mechanisms of obesity. Some perioperative biological samples (blood, DNA, adipose tissue, liver, intestine) were temporally collected in the surgical cohort of HUPNVS, leading to several research projects and international publications.

The team focuses on the mechanisms of gastrointestinal changes during obesity and bariatric surgery and previously showed profound changes in intestinal architecture, permeability, transport functions, metabolism, or in neuro-hormonal activity of the digestive tract. In these studies, it has been observed a plasticity of the epithelial cells constituting the gastrointestinal tract (including endocrine cells and enterocytes) that needs to be further documented. This plasticity that affects self-renewal, endocrine and digestive system and enteric nervous system, may allow epithelia to adapt to changes in the luminal environment (nutritional changes, modification of the microbiota, etc.) induced by obesity and bariatric surgery. Similarly, the connections of gastrointestinal tract with other tissues involved in metabolism and in particular the liver and adipose tissues affected by chronic inflammation and whose functions are impaired during obesity should be explored.

Our hypothesis is that a better understanding of the physio-pathological consequences of obesity and bariatric surgery, notably on the gastrointestinal tract, may allow to improve the treatment of obesity and to find alternatives to bariatric surgery.

The constitution of this cohort will allow to relate clinical data and biological data obtained in different organs (for example, to study the link between weight loss or nutritional status and gastrointestinal plasticity and transport functions). The collection of the samples either during the first surgery, or during surgical revision in subjects still obese (weight loss failure) or who have lost weight (cholecystectomies, gastro-esophageal reflux ...) will make it possible to study the consequences of obesity, weight loss but also of bariatric surgery independently of weight loss. In addition, the involvement of different teams with different fields of expertise will allow to compare the data obtained by different approaches and in different organs and thus advance in the inter-organ communication underlying the pathophysiology of obesity (for example, to study the link between inflammation of adipose tissue, NASH and metabolic complications of obesity). The characterization of specific markers, notably by studying the gastric and intestinal proteome of morbidly obese subjects, may make it possible to identify populations that are more at risk of developing certain complications and to open avenues for targeted therapies according to the profile of the patients. Moreover, a better understanding of the mechanisms and the digestive impact of bariatric surgery, will help to find non-surgical therapeutic alternatives.

The main objective of this cohort study is thus to systematize the collection and the conservation of biological samples (blood, stomach, liver, intestine, adipose tissue) obtained during bariatric surgery, in obese subjects undergoing surgery (including sleeve gastrectomy, Roux-en-Y gastric bypass, or revisional intervention for complication (cholecystectomies, intractable gastro-esophageal reflux...) or weight regain in HUPNVS

The main projects that will rely on the data of this cohort relates thus to: the gastrointestinal plasticity in morbid obesity; the status of nutrient absorption and metabolism in morbid obesity and the impact of bariatric surgery; the characterization of the gastric and intestinal proteome in morbid obese subjects; the link between tissue inflammation (adipose tissue, liver) and metabolic disorders.

The inclusion will be carried out the day before the intervention. The informed consent will be collected by the nutritionist or surgeon, and the clinical data will be recorded (socio-demographic and anthropometric data, comorbidities, metabolic parameters, digestive explorations). The surgery (gastric bypass, sleeve gastrectomy or revision) will be performed laparoscopically, according to usual practice. Tissue samples will be taken at the surgical site as part of usual care for liver biopsy (evaluation of NASH in this high-risk population), stomach in case of sleeve gastrectomy, or stomach and intestine in case of gastric bypass. Pieces (about 1 cm3) will be kept for research, but the samples will not be larger than those made for usual care. Blood samples (4 samples of 7 ml) and adipose tissue samples (2 aliquots of 10-15 g) at both subcutaneous (cutaneous incisions for the trocars) and visceral (large epiploon exposed during the intervention) localizations, will be collected and stored for research. They do not constitute an additional risk for the patient compared to the surgical procedure itself, apart from a minimal risk of hematoma at the site of collection. All tissue samples will be fixed and / or frozen at -80 ° C and stored in the Department of Pathology of Bichat hospital. The blood samples collected during the research will be frozen at -80 ° C and stored in a safe freezer at the center of biological resources of Bichat hospital for a period of 25 years.

The samples will then be analyzed according to the studies carried out, in the Department of Pathology for anatomo-pathological and immuno-histological studies and in INSERM unit 1149 for functional studies, generation of gastric and intestinal organoids, messenger RNA expression and biological assays, and by the other research teams for inflammation studies. At the end of the research, the samples may be used for subsequent analyzes not foreseen in the protocol which may prove to be interesting in the context of the pathology studied (obesity) according to the evolution of scientific knowledge, provided that the patient is not opposed, after being informed, as indicated in the information / consent form.

The originality of this project comes from the fact that at the moment there are very few teams in this topic that are organized to collect both precise phenotype (anthropometric data, co-morbidities) and systematic per-operative samples in patients with severe obesity. The current cohort project will allow to realize larger projects that will federate medico-surgical teams and INSERM researchers of HUPNVS. In addition, this project will facilitate interactions with other research units outside the hospital group by making available the stored samples, on topics related to obesity.

Keywords
obesity, bariatric surgery, gastrointestinal functions, adipose tissu, steatohepatitis
Medical subject headings
Obesity, Morbid, Obesity, Fatty Liver

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. number of biological samples collected

    liver stomach and intestin samples will be performed during surgery for usual care. Adiposes tissues and blood samples will be performed for reseach, on the surgical site

    Measured: during surgery

Secondary outcomes (4)
  1. modifications of gastro-intestinal plasticity induces by obesity and bariatric surgery

    gene expression of basic helix-loop-helix transcription factors (fold increase as compared to control)

    Measured: samples collected during surgery

  2. alterations of absroption and metabolism of nutriments induced by obesity and bariatric surgery

    intestinal protein expression of monosaccharides, proteins, fatty acids and cholesterol transporters (fold increase as compare to control)

    Measured: samples collected during surgery

  3. gastric and intestinal proteome

    gastric and intestinal proteome in the obese morbid subject assessed by mass spectrometry

    Measured: samples collected during surgery

  4. tissue inflammation and fibrosis

    quantification of the inflammatory infiltrate of the visceral and subcutaneous adipose tissue, liver and intestine (number per area)

    Measured: samples collected during surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 May 2018
  2. Study start16 Feb 2018
  3. Primary completion3 Mar 2026
  4. Study completion3 Mar 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
360 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03538210
Sponsor's protocol ID
K170704J
Acronym
COBILOM
Status last verified
Mar 2026
First submitted
6 Mar 2018
Last updated
31 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Severe Obesity and Bariatric Surgery, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

number of biological samples collected (time frame: during surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in